DE60138612D1 - Alen region des hepatitis virus orf2 kodierendes nukleinsäurekonstrukt und antigenes polypeptid - Google Patents

Alen region des hepatitis virus orf2 kodierendes nukleinsäurekonstrukt und antigenes polypeptid

Info

Publication number
DE60138612D1
DE60138612D1 DE60138612T DE60138612T DE60138612D1 DE 60138612 D1 DE60138612 D1 DE 60138612D1 DE 60138612 T DE60138612 T DE 60138612T DE 60138612 T DE60138612 T DE 60138612T DE 60138612 D1 DE60138612 D1 DE 60138612D1
Authority
DE
Germany
Prior art keywords
nucleic acid
acid construct
polypeptide
antigenous
hepatitis virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60138612T
Other languages
German (de)
English (en)
Inventor
Fan Li
David Andrew Anderson
Damian Francis Purcell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Burnet Institute
Original Assignee
Burnet Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Burnet Institute filed Critical Burnet Institute
Application granted granted Critical
Publication of DE60138612D1 publication Critical patent/DE60138612D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/28011—Hepeviridae
    • C12N2770/28111—Hepevirus, e.g. hepatitis E virus
    • C12N2770/28122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
DE60138612T 2000-03-31 2001-03-30 Alen region des hepatitis virus orf2 kodierendes nukleinsäurekonstrukt und antigenes polypeptid Expired - Fee Related DE60138612D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPQ6616A AUPQ661600A0 (en) 2000-03-31 2000-03-31 A nucleic acid construct and methods related thereto
PCT/AU2001/000353 WO2001073078A1 (en) 2000-03-31 2001-03-30 A nucleic acid construct encoding a processing component derived from the n-terminal region of the hepatitis virus orf2, and an antigenic polypeptide

Publications (1)

Publication Number Publication Date
DE60138612D1 true DE60138612D1 (de) 2009-06-18

Family

ID=3820712

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60138612T Expired - Fee Related DE60138612D1 (de) 2000-03-31 2001-03-30 Alen region des hepatitis virus orf2 kodierendes nukleinsäurekonstrukt und antigenes polypeptid

Country Status (14)

Country Link
US (1) US7341723B2 (cg-RX-API-DMAC7.html)
EP (1) EP1274851B1 (cg-RX-API-DMAC7.html)
JP (1) JP2003528614A (cg-RX-API-DMAC7.html)
KR (1) KR100768051B1 (cg-RX-API-DMAC7.html)
CN (1) CN1426472A (cg-RX-API-DMAC7.html)
AT (1) ATE430804T1 (cg-RX-API-DMAC7.html)
AU (1) AUPQ661600A0 (cg-RX-API-DMAC7.html)
CA (1) CA2407036A1 (cg-RX-API-DMAC7.html)
DE (1) DE60138612D1 (cg-RX-API-DMAC7.html)
HK (1) HK1052368A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA02009437A (cg-RX-API-DMAC7.html)
NZ (1) NZ521758A (cg-RX-API-DMAC7.html)
WO (1) WO2001073078A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200207769B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8101189B2 (en) 2002-07-05 2012-01-24 Folia Biotech Inc. Vaccines and immunopotentiating compositions and methods for making and using them
MXPA05000287A (es) 2002-07-05 2005-09-08 Leclerc Denis Particula viral adyuvante.
KR100641810B1 (ko) * 2004-04-23 2006-11-06 주식회사 포스코건설 충격흡수 및 복원 가능한 중간 스프링 설치 금속재 지주
US8906863B2 (en) 2009-02-27 2014-12-09 The Regents Of The University Of California Proteolysis-resistant capsid of chimeric hepatitis E virus as an oral delivery vector
US8906862B2 (en) 2009-02-27 2014-12-09 The Regents Of The University Of California Multiple antigen delivery system using hepatitis E virus-like particle
WO2010099547A1 (en) * 2009-02-27 2010-09-02 The Regents Of The University Of California Multiple antigen delivery system using hepatitis e virus-like particle

Also Published As

Publication number Publication date
JP2003528614A (ja) 2003-09-30
ATE430804T1 (de) 2009-05-15
AUPQ661600A0 (en) 2000-05-04
KR20030015223A (ko) 2003-02-20
EP1274851A1 (en) 2003-01-15
MXPA02009437A (es) 2006-05-25
EP1274851B1 (en) 2009-05-06
WO2001073078A1 (en) 2001-10-04
KR100768051B1 (ko) 2007-10-18
ZA200207769B (en) 2004-02-10
EP1274851A4 (en) 2004-12-08
US7341723B2 (en) 2008-03-11
CN1426472A (zh) 2003-06-25
NZ521758A (en) 2004-05-28
HK1052368A1 (zh) 2003-09-11
CA2407036A1 (en) 2001-10-04
US20030158138A1 (en) 2003-08-21

Similar Documents

Publication Publication Date Title
DE60117978D1 (de) Modifizierung des hepatitis b kernantigens
ATE433491T1 (de) Oligomerische komplexe von chimären proteinen mit verbessertem immunogenen potential
SE9003978D0 (sv) Dna expressionssystem baserade paa ett virus replikon
ATE325882T1 (de) Polypeptide, die mit alfalfamosaikviralen oder ilarviralen kapsiden fusioniert sind
NZ545048A (en) Chimeric antigens for breaking host tolerance to foreign antigens
ATE340859T1 (de) Rekombinantes papillomavirus l1 protein
EP0835315A4 (en) VACCINE AGAINST THE VIRUS RESPONSIBLE FOR RESPIRATORY AND REPRODUCTION DISEASES IN PIGS
DK1829551T3 (da) Modificeret varmchokprotein-antigenpeptid-kompleks
NZ234615A (en) Hepatitis b antigen; recombinant production
MXPA02006888A (es) Flavivirus recombinantes y metodos para utilizar los mismos.
CA2505942A1 (en) West nile virus vaccine
MXPA05005202A (es) Vacuna.
EP1015009A4 (en) attenuated VIF DNA immunization cassettes as genetic vaccines
ATE430804T1 (de) Für eine prozessierungskomponente aus der n- terminalen region des hepatitis virus orf2 kodierendes nukleinsäurekonstrukt und antigenes polypeptid
IE870507L (en) Bovine virus diarrhea and hog cholera vaccines
RU99108121A (ru) Иммуногенные пептиды вирусов ящура
YU45292A (sh) Različiti površinski proteini hepatitis b virusa koji obrazuju čestice
TW200509964A (en) VP1 of foot-and-mouth disease virus
EP0652769A1 (en) Vaccines against Metazoon parasites.
ATE71534T1 (de) Vakzine.
DE60027581D1 (de) Design von immunogene
JP2003528614A5 (cg-RX-API-DMAC7.html)
SE0002498D0 (sv) Papillomavirus vaccine
CN1986562B (zh) 一种能增强动物抗体应答的多肽片段及其应用
AU6839598A (en) Antigenic structural peptide, antigenic and immunogenic compounds and uses for detecting, preventing and treating an hcv infection

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee